Ironwood Pharmaceuticals Inc (FRA:I76)
€ 4.54 -0.1 (-2.16%) Market Cap: 735.32 Mil Enterprise Value: 1.22 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 55/100

Ironwood Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 12:00PM GMT
Release Date Price: €9.72 (-2.41%)
Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Good morning, everyone. My name is Balaji Prasad. I'm the Senior Analyst for the Spec Pharma coverage for Barclays.

So kick starting the day for the Barclays Annual Global Healthcare Conference, we have the pleasure of having the management team from Ironwood with us. So, Tom McCourt, CEO; and Greg Martini, Vice President, Strategic Finance and Investor Relations.

Tom and Greg, thank you so much for joining us today. So, we have around 25 minutes. In terms of the organization, why don't we start with just couple of recaps, you reported a few weeks ago? Maybe a couple of recaps and then we can go into Q&A.

Thomas A. McCourt
Ironwood Pharmaceuticals, Inc. - CEO & Director

Sure. So as you know, Ironwood is a GI-focused health care company with a lead asset, LINZESS, which is now considered a blockbuster in terms of US net sales. We have really 3 strategic imperatives. First of all, of course, maximize LINZESS. Second, how do we continue to advance our GI portfolio; and 3

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot